170 related articles for article (PubMed ID: 31898864)
1. Differences in patient ascertainment affect the use of gene-specified ACMG/AMP phenotype-related variant classification criteria: Evidence for TP53.
Fortuno C; Pesaran T; Dolinsky J; Yussuf A; McGoldrick K; Goldgar D; James PA; Spurdle AB
Hum Mutat; 2020 Mar; 41(3):537-542. PubMed ID: 31898864
[TBL] [Abstract][Full Text] [Related]
2. Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants.
Fortuno C; Lee K; Olivier M; Pesaran T; Mai PL; de Andrade KC; Attardi LD; Crowley S; Evans DG; Feng BJ; Foreman AKM; Frone MN; Huether R; James PA; McGoldrick K; Mester J; Seifert BA; Slavin TP; Witkowski L; Zhang L; Plon SE; Spurdle AB; Savage SA;
Hum Mutat; 2021 Mar; 42(3):223-236. PubMed ID: 33300245
[TBL] [Abstract][Full Text] [Related]
3. Challenges and approaches to calibrating patient phenotype as evidence for cancer gene variant classification under ACMG/AMP guidelines.
Fortuno C; Michailidou K; Parsons M; Dolinsky JS; Pesaran T; Yussuf A; Mester JL; Hruska KS; Hiraki S; O'Connor R; Chan RC; Kim S; Tavtigian SV; Goldgar D; James PA; Spurdle AB
Hum Mol Genet; 2024 Apr; 33(8):724-732. PubMed ID: 38271184
[TBL] [Abstract][Full Text] [Related]
4. Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines.
Fortuno C; Mester J; Pesaran T; Weitzel JN; Dolinsky J; Yussuf A; McGoldrick K; Garber JE; Savage SA; Khincha PP; Gareth Evans D; Achatz MI; Nichols KE; Maxwell KN; Schiffman JD; Sandoval R; ; James PA; Spurdle AB
Hum Mutat; 2020 Sep; 41(9):1555-1562. PubMed ID: 32485079
[TBL] [Abstract][Full Text] [Related]
5. Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing.
Rana HQ; Gelman R; LaDuca H; McFarland R; Dalton E; Thompson J; Speare V; Dolinsky JS; Chao EC; Garber JE
J Natl Cancer Inst; 2018 Aug; 110(8):863-870. PubMed ID: 29529297
[TBL] [Abstract][Full Text] [Related]
6. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants.
Lee K; Krempely K; Roberts ME; Anderson MJ; Carneiro F; Chao E; Dixon K; Figueiredo J; Ghosh R; Huntsman D; Kaurah P; Kesserwan C; Landrith T; Li S; Mensenkamp AR; Oliveira C; Pardo C; Pesaran T; Richardson M; Slavin TP; Spurdle AB; Trapp M; Witkowski L; Yi CS; Zhang L; Plon SE; Schrader KA; Karam R
Hum Mutat; 2018 Nov; 39(11):1553-1568. PubMed ID: 30311375
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of VUS reclassification in a single-centre series from application of ACMG/AMP classification rules specified for
Innella G; Ferrari S; Miccoli S; Luppi E; Fortuno C; Parsons MT; Spurdle AB; Turchetti D
J Med Genet; 2024 Apr; 61(5):483-489. PubMed ID: 38160042
[TBL] [Abstract][Full Text] [Related]
8. Variant Classification for Pompe disease; ACMG/AMP specifications from the ClinGen Lysosomal Diseases Variant Curation Expert Panel.
Goldstein JL; McGlaughon J; Kanavy D; Goomber S; Pan Y; Deml B; Donti T; Kearns L; Seifert BA; Schachter M; Son RG; Thaxton C; Udani R; Bali D; Baudet H; Caggana M; Hung C; Kyriakopoulou L; Rosenblum L; Steiner R; Pinto E Vairo F; Wang Y; Watson M; Fernandez R; Weaver M; Clarke L; Rehder C
Mol Genet Metab; 2023; 140(1-2):107715. PubMed ID: 37907381
[TBL] [Abstract][Full Text] [Related]
9. Suspected clonal hematopoiesis as a natural functional assay of TP53 germline variant pathogenicity.
Fortuno C; McGoldrick K; Pesaran T; Dolinsky J; Hoang L; Weitzel JN; Beshay V; San Leong H; James PA; Spurdle AB
Genet Med; 2022 Mar; 24(3):673-680. PubMed ID: 34906512
[TBL] [Abstract][Full Text] [Related]
10. ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants.
Luo X; Feurstein S; Mohan S; Porter CC; Jackson SA; Keel S; Chicka M; Brown AL; Kesserwan C; Agarwal A; Luo M; Li Z; Ross JE; Baliakas P; Pineda-Alvarez D; DiNardo CD; Bertuch AA; Mehta N; Vulliamy T; Wang Y; Nichols KE; Malcovati L; Walsh MF; Rawlings LH; McWeeney SK; Soulier J; Raimbault A; Routbort MJ; Zhang L; Ryan G; Speck NA; Plon SE; Wu D; Godley LA
Blood Adv; 2019 Oct; 3(20):2962-2979. PubMed ID: 31648317
[TBL] [Abstract][Full Text] [Related]
11. Evaluating ClinGen variant curation expert panels' application of PVS1 code.
Wang X; Li H; Luo H; Zou Y; Li H; Qin Y; Song J
Eur J Med Genet; 2024 Feb; 67():104909. PubMed ID: 38199457
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of functional assay evidence use by ClinGen Variant Curation Expert Panels.
Kanavy DM; McNulty SM; Jairath MK; Brnich SE; Bizon C; Powell BC; Berg JS
Genome Med; 2019 Nov; 11(1):77. PubMed ID: 31783775
[TBL] [Abstract][Full Text] [Related]
13. Quantification of Discordant Variant Interpretations in a Large Family-Based Study of Li-Fraumeni Syndrome.
Frone MN; Stewart DR; Savage SA; Khincha PP
JCO Precis Oncol; 2021; 5():. PubMed ID: 34805717
[TBL] [Abstract][Full Text] [Related]
14. Specifications of the ACMG/AMP variant curation guidelines for myocilin: Recommendations from the clingen glaucoma expert panel.
Burdon KP; Graham P; Hadler J; Hulleman JD; Pasutto F; Boese EA; Craig JE; Fingert JH; Hewitt AW; Siggs OM; Whisenhunt K; Young TL; Mackey DA; Dubowsky A; Souzeau E
Hum Mutat; 2022 Dec; 43(12):2170-2186. PubMed ID: 36217948
[TBL] [Abstract][Full Text] [Related]
15. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically.
Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D
Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007
[TBL] [Abstract][Full Text] [Related]
16. Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium.
Amendola LM; Jarvik GP; Leo MC; McLaughlin HM; Akkari Y; Amaral MD; Berg JS; Biswas S; Bowling KM; Conlin LK; Cooper GM; Dorschner MO; Dulik MC; Ghazani AA; Ghosh R; Green RC; Hart R; Horton C; Johnston JJ; Lebo MS; Milosavljevic A; Ou J; Pak CM; Patel RY; Punj S; Richards CS; Salama J; Strande NT; Yang Y; Plon SE; Biesecker LG; Rehm HL
Am J Hum Genet; 2016 Jun; 98(6):1067-1076. PubMed ID: 27181684
[TBL] [Abstract][Full Text] [Related]
17. TP53 variants of uncertain significance: increasing challenges in variant interpretation and genetic counseling.
Bittar CM; Vieira IA; Sabato CS; Andreis TF; Alemar B; Artigalás O; Galvão HCR; Macedo GS; Palmero EI; Ashton-Prolla P
Fam Cancer; 2019 Oct; 18(4):451-456. PubMed ID: 31321604
[TBL] [Abstract][Full Text] [Related]
18. Identification and Management of
Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
[TBL] [Abstract][Full Text] [Related]
19. Disease-specific ACMG/AMP guidelines improve sequence variant interpretation for hearing loss.
Patel MJ; DiStefano MT; Oza AM; Hughes MY; Wilcox EH; Hemphill SE; Cushman BJ; Grant AR; Siegert RK; Shen J; Chapin A; Boczek NJ; Schimmenti LA; Nara K; Kenna M; Azaiez H; Booth KT; Avraham KB; Kremer H; Griffith AJ; Rehm HL; Amr SS; Tayoun ANA;
Genet Med; 2021 Nov; 23(11):2208-2212. PubMed ID: 34230634
[TBL] [Abstract][Full Text] [Related]
20. Adapting the ACMG/AMP variant classification framework: A perspective from the ClinGen Hemoglobinopathy Variant Curation Expert Panel.
Kountouris P; Stephanou C; Lederer CW; Traeger-Synodinos J; Bento C; Harteveld CL; Fylaktou E; Koopmann TT; Halim-Fikri H; Michailidou K; Nfonsam LE; Waye JS; Zilfalil BA; Kleanthous M;
Hum Mutat; 2022 Aug; 43(8):1089-1096. PubMed ID: 34510646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
